Objective To evaluate the association between newborn acylcarnitine profiles and the subsequent development of necrotizing enterocolitis (NEC) with the use of routinely collected newborn screening data in infants born preterm. Results Fourteen acylcarnitine levels and acylcarnitine ratios were associated with increased risk of developing NEC. Each log unit increase in C5 and free carnitine /(C16 + 18:1) was associated with a 78% and a 76% increased risk for developing NEC, respectively (OR 1.78, 95% CI 1.53-2.02, and OR 1.76, 95% CI 1.51-2.06). Six acylcarnitine levels, along with birth weight and total parenteral nutrition, identified 89.8% of newborns with NEC in the model-development cohort (area under the curve 0.898, 95% CI 0.889-0.907) and 90.8% of the newborns with NEC in the validation cohort (area under the curve 0.908, 95% CI 0.901-0.930).
Metabolic profiling through newborn screening may serve as an objective biologic surrogate of risk for the development of disease and thus facilitate disease-prevention strategies. (J Pediatr 2017;181:80-5).
See editorial, p 9 N ecrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality among infants born preterm. NEC is an acquired disease of the neonatal period marked by inflammation and necrosis of the gastrointestinal tract. The ambiguity of presenting symptoms of NEC and the low specificity of common diagnostic tests may lead to delayed diagnosis and treatment. 1 The underlying pathophysiology of NEC appears to be multifactorial, involving a combination of developmental immaturity, variable feeding practices, and bacterial colonization of the gut. 2 Metabolism emerges at the intersection of these predisposing variables as an underexplored feature that likely impacts disease onset. Because no previous studies conclusively have identified high-risk infants based on measurable predisposing biologic features, there has been little progression in the understanding of the inciting pathophysiologic basis for NEC beyond prematurity. [3] [4] [5] Abnormal fatty and organic acid metabolism of prematurity as indicated by acylcarnitine profiles may be implicated in the pathogenesis of NEC. Prematurityassociated disturbances in nutrient metabolism, enteric dysmotility, and gut colonization may result in excess fermentation and the accumulation of organic and short-chain fatty acids that have been shown to contribute to intestinal mucosal injury and necrosis in both human subjects and animal models that closely mimic human NEC. [6] [7] [8] [9] [10] We hypothesized that an association between newborn acylcarnitine profiles and the subsequent development of NEC could further refine age-and weight-associated risk in biologic terms. 
Acylcarnitine Measurements
Acylcarnitine measurements, hours/days after birth at testing, race/ethnicity, and information about whether the infant had been on total parenteral nutrition between birth and the time of testing were obtained from the newborn screening records. Birth certificate and hospital discharge records were linked to newborn screening data through the California Office of Statewide Health Planning and Development to obtain information on total days gestation, birth weight, and diagnosis of NEC (by International Statistical Classification of Diseases, Ninth Revision, code 777.5). Details regarding the newborn screening program and testing of acylcarnitine levels have been described in detail. 11, 12 All newborns included in the present study had acylcarnitine levels measured in dried blood specimens collected by heel-stick at birth hospitals between 12 hours and 8 days after birth.
Following collection, specimens were sent to a stateapproved laboratory for testing with a standardized tandem mass spectrometry assay (MS 2 2000 system; PerkinElmer Life Sciences, Shelton, Connecticut). Specimens were tested with a NeoGram acylcarnitine derivatized reagent kit (PerkinElmer). For all samples, testing was based on the MS 2 system operated in the positive ion mode (source voltage: 5500 V). Acylcarnitine levels were measured by precursor ion scanning with precursors of m/z 85 and quantitated by comparison with stable-isotope internal standards. All information on acylcarnitine levels measured as part of routine newborn screening was included in the analyses. This included values for 20 acylcarnitines (C2, C3, C3DC, C4, C5, C5:1, C5DC, C6, C8, C8:1, C10, C10:1, C12, C14, C14:1, C16, C16:1, C18, C18:1, C18:1OH, and free carnitine [FC] ) and 2 acylcarnitine ratios (FC/[C16 + C18:1] and C3/C2).
Model Development and Validation Cohort Analyses
Two analyses were conducted. First, the association between acylcarnitine levels and a subsequent diagnosis of NEC was 
Analysis of Individual Acylcarnitine Levels
Crude association testing in the model-development cohort included the comparison of newborns born preterm with and without NEC by characteristic and by the log of acylcarnitine level and ratio. The c 2 test was used to compare groups by race/ ethnicity, sex, total parenteral nutrition (yes or no), age in days at acylcarnitine testing, and gestational age (gestational age <32, 32-36 weeks) by birth weight grouping (<1500, 1500-2499, ≥2500 g). Race/ethnicity was derived from the birth certificate record, where the reporting parent selected from a list of predefined categories. The 2-tailed Wilcoxon rank sum test was used for the initial comparison of the distribution of acylcarnitine level and ratios between infants born preterm with and without NEC. Logistic regression was used to calculate ORs and 95% CIs to identify the relationship between a natural log-unit increase in acylcarnitine levels or ratios and the risk of NEC wherein both crude-and characteristic-adjusted risks were evaluated.
Multivariate Analysis of Acylcarnitine Levels
Final model development for combined characteristic and acylcarnitine effects used backward stepwise regression methods in which P < .10 was used as the threshold for entering the model and P < .05 was used as the threshold for remaining. We evaluated the performance of the final logistic model for NEC prediction in both the model-development and validation cohorts. Receiver operator characteristic curves and associated area under the curve (AUC) statistics were evaluated overall, by day of testing, and by gestational age. All analyses were performed with SAS Software, version 9.3 (SAS Institute, Cary, North Carolina) based on data received by the Genetic Disease Screening Program as of December 31, 2013.
Results
Most newborns in the model-development cohort were Hispanic (50.92%) or non-Hispanic white (27.05%) and had newborn screening obtained between 12 hours and 2 days of life (69.18%). Approximately 1 in 127 infants born preterm ultimately was diagnosed with NEC. Of those who developed NEC, the greatest frequency was seen in newborns with births before 32 completed weeks of gestation with birth weight < 1500 g ( Table I ). Preterm newborns with NEC in the model-development and validation cohorts differed from those without NEC by race/ethnicity, use of total parenteral nutrition at the time of testing, day of life at testing, and by gestational age by birth weight grouping ( Table I) .
Analysis of Individual Acylcarnitines
The distribution of acylcarnitine levels and acylcarnitine ratios in infants born preterm with and without NEC differed across Volume 181 • February 2017 all measures except for log C2, log C6, and log C18:1OH (Table II ; available at www.jpeds.com). Fourteen of the 23 acylcarnitine measures were associated with per log unit increases in NEC risk after adjustment for race/ethnicity, use of total parenteral nutrition, days at test (by grouping), and gestational age by birth weight grouping (Table III ; available at www.jpeds.com). Each log unit increase in C5 was associated with a 78% increased risk for NEC after adjustment (OR 1.78, 95% CI 1.53-2.02). Each log unit increase in FC/(C16 + 18:1) was associated with a 76% increase in risk for NEC after adjustment (OR 1.76, 95% CI 1.51-2.06) ( Table III) .
Combined Risk of NEC Acylcarnitines Model
When patient characteristics, acylcarnitine levels, and acylcarnitine ratios were evaluated together, 5 acylcarnitines (log C5, log C5:1, log C8:1, log C12, log C14:1), 1 acylcarnitine ratio (log FC/[C16 + C18:1]), gestational age by birth weight grouping, and the use of total parenteral nutrition were significantly associated with NEC at P < .05 (Table IV) . This combination of factors correctly grouped infants born preterm with and without NEC 89.8% of the time (AUC 0.8983, 95% CI 0.8895-0.9072) in the model-development cohort and 90.8% of the time (AUC 0.9078, 95% CI 0.8903-0.9253) in the validation cohort (Table V) .
Acylcarnitines, Prematurity, and Biologic Vulnerability
Model performance was the best among those with newborn screening obtained between 12 hours and 2 days of life (AUC 0.9339, 95% CI 0.9236-0.9440 in the model-development cohort BW, birth weight. *P < .001. †A total of 36 preterm births in the "No NEC" grouping in the model-development set and 9 preterm births in the "No NEC" grouping in the validation set had no sex designation. GA, gestational age; TPN, total parenteral nutrition. *<32 wk by <1500 g, 1500-2499 g, and ≥2500 g and 32-36 wk by <1500 g, 1500-2499 g, and ≥2500 g. †ORs are per log unit increase in AC levels, change in group for GA by BW, and TPN yes and no adjusted for all other factors in the model.
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and AUC 0.9518, 95% CI 0.9380-0.9655 in the validation cohort) ( Table V) . When characteristics and acylcarnitine levels were considered in isolation, both sets of factors were associated with AUCs > 85% overall, >70% in newborns with gestational ages < 32 weeks, and >80% in newborns with gestational ages between 32 and 36 weeks in both the modeldevelopment and validation cohorts (Table VI) . In both the development and validation cohorts, increased AUCs were observed when characteristics and acylcarnitine levels were considered together, although, in general, increases were modest.
Discussion
This study demonstrated an association between fatty acid metabolism assessed with the use of acylcarnitine profiles and the risk of NEC in newborns born premature. These data suggest that metabolic profiles obtained shortly after birth may reflect biologic vulnerability before alteration by clinical care. This study also indicates that widely available newborn screening data can be developed for use in risk stratification in neonatal diseases such as NEC. Previous biomarker studies have attempted to identify highrisk populations early in the course of disease and to differentiate NEC from other neonatal inflammatory conditions. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] These reports focused largely on inflammatory pathways and used combinations of nonspecific markers that failed to identify high-risk infants in a time frame that would allow implementation of disease-prevention strategies. Our results introduce the concept of using newborn metabolic screening at birth to identify metabolic dysfunction and a possible link to NEC, an acquired disease of prematurity. Accordingly, acylcarnitine levels measured within the first several days of life may provide an opportunity for early risk stratification and a method for testing various metabolism-based prevention strategies, including probiotics or modified feeding protocols, that have shown some promise in previous clinical studies. 23, 24 The underlying pathophysiology of NEC is understood incompletely and likely is multifactorial. The combination of prematurity, variable feeding practices, and bacterial colonization are implicated consistently as the major predisposing factors.
1,2
Although the proximal event leading to mucosal injury is not well defined, it is conceivable that newborns born premature are predisposed to NEC as a result of compromised fatty acid metabolism. Because acylcarnitines are derived from the metabolism of fatty and organic acids, it is plausible that abnormal systemic fatty acid oxidation predisposes to gut-specific toxicity following the introduction of a metabolic challenge as occurs with enteral feedings. It has been reported previously in animal models of prematurity that exposure of the intestinal mucosa to fatty acid derivatives causes mucosal necrosis. 7, 8, 25 NEC is diagnosed most commonly after the initiation of enteral feeding and may be related to both the timing (early or late) of initiation of enteral feedings and rate of feeding advancement, thus implying that increased exposure of the premature gastrointestinal lumen to gut fermentation products including fatty and organic acids produces NEC-inciting injury. [26] [27] [28] It is intriguing that total parenteral nutrition appears to be a risk factor for the development of NEC both in this study and others. 29 It is unclear whether total parenteral nutrition is exacerbating metabolic dysfunction or is simply a surrogate for sicker infants born preterm who begin enteral feeding in a delayed manner. Importantly, the acylcarnitine-NEC association described in this study was most accurate for infants who underwent screening within the first 48 hours of life, perhaps suggesting that metabolic profiling may reflect development-dependent metabolic dysfunction. Additional studies that evaluate the gastrointestinal toxicity of dysfunctional metabolism involving fatty acid oxidation in both laboratory and clinical studies of NEC are warranted to confirm these speculations.
Despite good overall model sensitivity, the utility of the current acylcarnitine-based model as a clinical tool requires additional consideration. The addition of other routinely measured metabolic variables (eg, amino acids) and serial testing may both improve the statistical performance and positive predictive value of metabolic profiling as a clinical prediction tool as well as account for clinical care confounding and influence on metabolic risk longitudinally. A reasonable objective may be to use the present metabolic model to facilitate the development of novel management and prevention strategies based on metabolic profiling. The potential risks and benefits of promising NEC-prevention strategies (including monitored feeding protocols and/or probiotics) are subject to ongoing study 27, 30 ; however, given the substantial NECrelated mortality as well as the possibility of significant lifelong gastrointestinal and neurologic impairment in survivors, the potential benefit from the prevention of any case of NEC should be viewed as highly significant compared with the potential for harm of perceived low-risk interventions.
The strengths of the present study include the use of population-based metabolic screening data linked to a comprehensive neonatal outcomes database. This combination has expanded the novel application of linking newborn screening results to acquired newborn disease. 31, 32 Our study population included infants born preterm from across the broad geographic and socioeconomic regions of California, and the results remained robust while we controlled for multiple patient demographic factors. In light of these strengths, it also should be recognized that there are important limitations to the present study. The use of a population-based dataset meant that we relied exclusively on hospital discharge records for NEC diagnosis and were therefore limited in our ability to stratify results by severity of disease (progressive and nonprogressive NEC) through the examination of clinical records. Furthermore, the validation cohort also was derived from California births (albeit in a different year), and this may have led to some overfitting of the model. These issues point to the importance of testing the relationships observed in the current study in other populations where a tighter phenotypic description is possible. Accordingly, subsequent efforts will benefit from a focus on targeted age and size cohorts (eg, <32, or 32-26 weeks) exclusively, given the discussed etiologic and clinical implications.
The observed association between acylcarnitine profile and NEC offers the potential for early identification of high-risk newborns based on metabolism using an available testing platform and represents an important first step towards directing preventive measures and developing improved therapeutic strategies. The present findings suggest that NEC may be the manifestation of a predisposing systemic metabolic dysfunction, thus providing new insights into the pathophysiology of NEC.
In conclusion, abnormal acylcarnitine profiles measured during newborn screening were associated with increased risk for NEC in infants born premature. Replication and external validation of the findings may lead to the development of novel prevention strategies. A lthough migraine headache has been recognized since "the close of the eighteenth century," our understanding of the pathophysiology of this disorder has advanced greatly over the past 50 years with the help of imaging studies and identification of specific pathways involved in migraine. This has led to advances in targeted treatments for migraine, with many more potential targets remaining to be explored.
When Holguin and Fenichel studied 55 children with migraine 50 years ago, their descriptive grouping included a preheadache/vasconstrictive phase, a headache/vasodilatative phase, and a postheadache stage, reflecting their understanding of migraine as a primarily vascular event. Since then, there has been a steady accumulation of data indicating that migraine is a primary brain disorder in which neural events lead to vasodilation, which leads to pain and further nerve activation (via the reflex connections of the trigeminal nervous system with the cranial parasympathetic outflow). The older concept that migraine itself is due to a reactive vasodilation following the vasoconstrictive aura has been superseded by the idea that the aura and headache are 2 processes occurring in parallel, both driven by the same triggering "neural events."
A better understanding of this migraine process has been gained with the aid of such techniques as magnetic resonance imaging, which allows for noninvasive evaluation of cerebral vasculature as well as measurement of cerebral blood flow and brain energy metabolism. This is a far cry from the days of X-rays of the skull, pneumoencephalography (involving injection of air into the ventricles of the brain), and direct carotid arteriography.
From a therapeutic standpoint, the use of ergotamines and methylsergide has been replaced by therapy with triptans, which also target the serotonin pathway but produce fewer side effects. Other targets currently under study include 
